Clinical trials have demonstrated that POM3 treatment at a dose of 4.0 g ... improves the lipid profile of patients with persistent hypertriglyceridemia to a greater extent than a statin alone ...

Data taken from [10,12,20,21]. Table 3. US National Cholesterol Education Program Adult Treatment Panel III LDL-C and non-HDL-C treatment goals. Risk category* LDL-C treatment goal Non-HDL-C ...

SG Americas Securities LLC lifted its holdings in 89bio, Inc. (NASDAQ:ETNB – Free Report) by 18.3% during the fourth quarter, ...

Learn more about whether Arrowhead Pharmaceuticals, Inc. or Veracyte, Inc. is a better investment based on AAII's A+ Investor ...

Fintel reports that on February 4, 2025, Wolfe Research initiated coverage of 89bio (NasdaqGM:ETNB) with a Outperform ...

Inc. (NASDAQ:ETNB), with a market capitalization of $1.14 billion, is a clinical-stage biopharmaceutical company focusing on the development of innovative therapies for the treatment of liver and ...

Learn more about whether Catalyst Pharmaceuticals, Inc. or Ionis Pharmaceuticals, Inc. is a better investment based on AAII's ...

Goldman Sachs & Co. LLC, Leerink Partners and BofA Securities acted as lead book-running managers and Cantor acted as book-running manager for the offering.

R Squared Ltd acquired a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The ...

Akero Therapeutics nearly doubled Monday — and pulled 89bio shares higher — after the company's treatment for MASH ... trial in patients with severe hypertriglyceridemia (SHTG); topline ...